William Mezzanotte
Chief Tech/Sci/R&D Officer chez CSL LIMITED
Profil
Actuellement, William Mezzanotte est Chief Medical Officer, EVP & Head-R&D chez CSL Ltd. Le Dr Mezzanotte siège également au conseil d'administration de BELLUS Health, Inc. et du University City Science Center. Auparavant, le Dr Mezzanotte était vice-président et chef des services respiratoires et de l'inflammation chez AstraZeneca Plc et premier vice-président et chef du domaine thérapeutique chez C.H. Boehringer Sohn AG & Co. KG. William Mezzanotte a obtenu un diplôme de premier cycle de l'université de Villanova, un doctorat de l'université de Pennsylvanie et un diplôme d'études supérieures de l'université Johns Hopkins.
Postes actifs de William Mezzanotte
| Sociétés | Poste | Début |
|---|---|---|
| CSL LIMITED | Chief Tech/Sci/R&D Officer | 01/10/2018 |
University City Science Center
 University City Science Center Investment Trusts/Mutual FundsMiscellaneous University City Science Center provides physical space, resources and other support to the community. The company was founded in 1963 and is headquartered in Philadelphia, PA. | Director/Board Member | 19/06/2020 |
Anciens postes connus de William Mezzanotte
| Sociétés | Poste | Fin |
|---|---|---|
| BELLUS HEALTH | Director/Board Member | 01/01/2023 |
C.H. Boehringer Sohn AG & Co. KG
 C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Corporate Officer/Principal | 01/04/2017 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/03/2015 |
CSL Behring LLC
 CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Chief Tech/Sci/R&D Officer | - |
Formation de William Mezzanotte
| University of Pennsylvania | Doctorate Degree |
| The Johns Hopkins University | Graduate Degree |
| Villanova University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| CSL LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
C.H. Boehringer Sohn AG & Co. KG
C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Health Technology |
University City Science Center
University City Science Center Investment Trusts/Mutual FundsMiscellaneous University City Science Center provides physical space, resources and other support to the community. The company was founded in 1963 and is headquartered in Philadelphia, PA. | Miscellaneous |
